Glenmark launches anti-osteoporosis drug

 Sharma added that the company was planning to garner 4.5% of the Rs 156 crore market in its first year.

 The active pharmaceutical ingredient (API) for the drug would be manufactured at the company's plant at Ankleshwar in Gujarat while the formulations would be manufactured at its Kurkum plant in Maharashtra, Sharma added.